Investment Rating - The report gives a "Buy" rating for the company, marking its first coverage [3]. Core Insights - The company is a leader in automotive intelligent driving perception and is expanding into the robotics sector, establishing a new growth curve [1][3]. - The demand for intelligent driving products is increasing due to the rapid penetration of advanced driver-assistance systems (ADAS) and supportive government policies [2][34]. - The company has a solid order backlog of approximately 20.9 billion yuan, indicating strong demand certainty [2]. Summary by Sections 1. Company Overview - The company has been focused on automotive intelligent driving perception systems since its establishment in 2010, achieving significant milestones such as large-scale production of automotive-grade ADAS millimeter-wave radar [15][16]. - In 2025, the company announced a partnership with NVIDIA to enter the robotics field, developing a control system for robots [15][17]. 2. Market Dynamics - The penetration rate of intelligent driving systems is rapidly increasing, with L2 and above ADAS installations reaching 10.98 million units in 2024, representing a penetration rate of 47.9% [35]. - The company benefits from the rising demand for sensors and domain controllers as the market for intelligent driving expands [2][34]. 3. Financial Performance - The company's revenue is projected to grow from 1.202 billion yuan in 2023 to 2.786 billion yuan in 2027, with a compound annual growth rate (CAGR) of 18% [5][25]. - The net profit attributable to the parent company is expected to fluctuate, with estimates of 0.99 billion yuan in 2025 and 1.76 billion yuan in 2027 [3][5]. 4. Product Development - The company is actively developing new products, including 4D millimeter-wave radar and various sensors to meet the safety redundancy requirements for L3 autonomous driving [17]. - The integration of perception and decision-making systems is a key focus, with the company aiming to enhance its competitive edge in both automotive and robotics sectors [3][17].

Investment Rating - The report maintains a "Buy" rating for the company [6][8]. Core Insights - The company is a leading player in the orthopedic surgical robot industry in China, focusing on reshaping surgical processes through intelligent technology and integrating upstream and downstream resources [3][16]. - The company has launched multiple generations of orthopedic surgical robots, with significant advancements in product capabilities and regulatory approvals, including the first all-in-one orthopedic surgical robot [3][5]. - The policy environment is becoming increasingly favorable for surgical robots, with expectations of broader inclusion in medical insurance coverage, which could significantly boost the company's market potential [4][48]. - The consumables and services segment is projected to become a major growth driver, with increasing surgical volumes and a growing demand for related services [5][28]. - Financial forecasts indicate strong revenue growth, with expected revenues of 275 million, 396 million, and 567 million yuan for 2025, 2026, and 2027 respectively, alongside a path to profitability by 2027 [6][9]. Company Overview - The latest closing price is 22.79 yuan, with a total market capitalization of 10.4 billion yuan [2]. - The company has a total share capital of 456 million shares, with a debt-to-asset ratio of 24.3% [2]. - The company has a unique business model that combines equipment sales, consumables, and technical services, aiming for a comprehensive service approach [24]. Market Dynamics - The global orthopedic surgical robot market is expected to grow significantly, driven by an aging population and the increasing demand for precise surgical interventions [31][36]. - The domestic market is characterized by a "one strong, many strong" competitive landscape, with the company holding over 40% market share in China [41][43]. - The report highlights the potential for rapid growth in the orthopedic surgical robot market, with projections indicating a compound annual growth rate of 33.3% from 2026 to 2030 [36][47]. Financial Performance - The company has maintained a high gross margin, with a sales gross margin of 70.2% in 2024, expected to improve further in subsequent years [30]. - Revenue for the first three quarters of 2025 reached 187 million yuan, reflecting a year-on-year growth of 103.5% [29][32]. - The company is on track to reduce losses, with forecasts indicating a return to profitability by 2027 [6][9].

Investment Rating - The report assigns a "Buy" rating to the company with a target price of 10.01 CNY [5][21]. Core Insights - The company is a long-established leader in the glass industry, accelerating its transformation with a focus on automotive glass and TCO (Transparent Conductive Oxide) glass production [2][11]. - The automotive glass market is rapidly expanding, with the company achieving nationwide operational rights and accelerating new vehicle partnerships, which is expected to enhance both volume and profitability [16][24]. - The TCO glass production is nearing mass production, with the company having a leading position in online coating technology, poised to benefit from the upcoming demand surge [17][18]. Financial Summary - The company’s total revenue is projected to reach 5.588 billion CNY in 2023, with a growth forecast of 10.3% to 6.418 billion CNY by 2027 [4][18]. - Net profit is expected to recover from a loss of 125 million CNY in 2023 to a profit of 279 million CNY by 2027, reflecting a significant turnaround [4][18]. - Earnings per share (EPS) are forecasted to increase from -0.13 CNY in 2023 to 0.29 CNY in 2027 [4][18]. Company Overview - The company, established in 1983, is a Sino-British joint venture, with major shareholders including Shanghai Building Materials Group and NSG Group [23][15]. - The governance structure is stabilizing, with Shanghai Building Materials Group increasing its shareholding over the years [31][15]. - The company is focusing on upgrading its deep processing capabilities through targeted fundraising for technological improvements [30][2]. Automotive Glass Market - The automotive glass segment is projected to grow significantly, with revenue expected to reach 20.86 billion CNY in 2025, driven by increased demand for electric and smart vehicles [18][19]. - The gross margin for automotive glass is anticipated to improve from 10.25% in 2023 to 15.00% by 2027, reflecting enhanced product offerings and customer partnerships [16][18]. - The competitive landscape in the automotive glass market is limited due to high capital requirements and operational complexities, favoring established players [39][41]. TCO Glass Production - The TCO glass segment is approaching a production ramp-up, with significant demand expected from downstream clients in the 2025-2027 period [17][18]. - The company’s acquisition of Dalian Yao Pi has improved its online coating utilization, contributing significantly to its profitability [17][18]. - The TCO glass production is supported by advancements in coating technology and resource availability, positioning the company favorably for future growth [17][18].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 53.84 CNY [4][7]. Core Insights - The company's short-term performance is under pressure due to intensified competition and policy impacts, leading to a downward revision of revenue and profit forecasts for 2025-2026 [4][10]. - Despite the short-term challenges, the company has significant long-term growth potential driven by self-research and innovation transformation [4][10]. - The company is expected to leverage its integrated service capabilities in contract research and development (CRO) and contract development and manufacturing organization (CDMO) to enhance its business structure and return to a growth trajectory [10]. - The company has a robust pipeline of self-researched products, with 132 projects under development, including 37 approved projects, which are anticipated to contribute positively to future revenues [10]. - The company is actively transitioning to innovative drug development, with 15 ongoing projects in critical therapeutic areas, which could provide a second growth curve through partnerships and milestone payments [10]. Financial Summary - Revenue is projected to decline from 1,017 million CNY in 2023 to 696 million CNY in 2025, with a recovery expected in subsequent years [6][12]. - The net profit attributable to the parent company is forecasted to be a loss of 53 million CNY in 2024, with a gradual return to profitability by 2026 [6][12]. - The earnings per share (EPS) is expected to drop to -0.63 CNY in 2025, before recovering to 0.37 CNY in 2026 and 0.61 CNY in 2027 [6][12]. - The gross margin is projected to decrease from 65.5% in 2023 to 52.0% in 2024, with a gradual recovery thereafter [6][12].

非银金融/证券Ⅱ 华泰证券（601688.SH） 再融资靴子落地，利好国际业务增长 2026 年 02 月 03 日 投资评级：买入（维持） 日期 2026/2/2 当前股价(元) 22.69 一年最高最低(元) 25.75/14.60 总市值(亿元) 2,048.20 流通市值(亿元) 1,657.90 总股本(亿股) 90.27 流通股本(亿股) 73.07 近 3 个月换手率(%) 80.96 股价走势图 数据来源：聚源 -32% -16% 0% 16% 32% 48% 64% 2025-02 2025-06 2025-10 华泰证券 沪深300 相关研究报告 《业绩超预期，综合实力行业领先— 华泰证券 2025 三季报点评》 -2025.10.31 高超（分析师） 卢崑（分析师） 证书编号：S0790520050001 lukun@kysec.cn 证书编号：S0790524040002 事件：2 月 3 日上午，华泰证券公告拟根据一般性授权发行可转换为本公司 H 股 股份的债券。 再融资靴子落地，利好国际业务增长 本次发行 H 股零息可转债（悉数转换后）一共对 H 股股份稀释 29.53%，对总股 ...

Investment Rating - The report maintains a rating of "Buy" for the company [6] Core Insights - The company is positioned as a cash cow in the cement industry, with a strong focus on cost control and profitability, leading to a competitive edge in the market [4][48] - The company is expanding into the semiconductor sector, with financial investments expected to yield returns starting in 2026, enhancing overall profitability [59][60] - The company aims to develop a dual-driven business model combining construction materials and equity investments, targeting a new growth curve in silicon-based materials [32][59] Summary by Sections Company Overview - The company, established in 1978, has a mixed ownership structure that combines the flexibility of private enterprises with the resources of state-owned enterprises, enhancing its competitive position [14] - As of Q3 2025, the company has a market capitalization of approximately 14.49 billion yuan and a significant cash reserve of 3.1 billion yuan, supporting its investment strategies [4][25] Cement Industry Analysis - The cement industry is expected to see improvements in supply-demand dynamics due to capacity replacement policies and government support for infrastructure projects [33][41] - The company has successfully implemented a T-shaped strategy similar to that of Conch Cement, leading to industry-leading cost and profit margins [48][49] Financial Performance - Revenue projections for 2025-2027 are estimated at 5.43 billion, 5.57 billion, and 5.72 billion yuan, with net profits expected to grow significantly during this period [6][7] - The company has a high dividend payout ratio, with a projected dividend of 6 billion yuan for 2024, reflecting a strong commitment to shareholder returns [5][27] Investment Strategy - The company has invested in over 20 semiconductor firms since 2020, focusing on various sectors within the semiconductor industry, which is anticipated to contribute significantly to profits in the coming years [59][60] - The establishment of a partnership with Lanpu Venture Capital aims to further enhance the company's investment capabilities in the semiconductor space [32][59]

Investment Rating - The report assigns a rating of "Buy" for the company with a target price of 10.01 CNY [5][21]. Core Insights - The company is a long-established leader in the glass industry, accelerating its transformation with a focus on automotive glass and TCO (Transparent Conductive Oxide) glass production [2][11]. - The automotive glass segment is expanding rapidly, with the company achieving nationwide operational rights and accelerating new vehicle partnerships, which is expected to enhance both volume and profitability [16][24]. - The TCO glass production is nearing mass production, with the company having a leading position in online coating technology, poised to benefit from the upcoming demand surge [17][18]. Financial Summary - Total revenue is projected to reach 5.588 billion CNY in 2023, with a growth forecast of 10.3% to 6.418 billion CNY by 2027 [4][18]. - The net profit attributable to shareholders is expected to recover from a loss of 125 million CNY in 2023 to a profit of 279 million CNY by 2027, reflecting a significant turnaround [4][18]. - Earnings per share (EPS) is forecasted to increase from -0.13 CNY in 2023 to 0.29 CNY in 2027 [4][18]. Company Overview - The company, established in 1983, is a Sino-British joint venture, with major shareholders including Shanghai Building Materials Group and NSG Group [23][31]. - The governance structure is stabilizing, with Shanghai Building Materials Group increasing its shareholding over the years [31][32]. - The business structure has shifted towards higher value-added products, particularly in automotive and TCO glass segments [15][24]. Automotive Glass Market - The automotive glass market is experiencing rapid expansion, with the value per vehicle increasing from approximately 500-800 CNY for traditional vehicles to 1500-2000 CNY for electric and smart vehicles [16][35]. - The company has unified its operational rights across the country and is accelerating the acquisition of new energy vehicle partnerships, which is expected to improve profit margins significantly [16][24]. - The gross margin for automotive glass is projected to rise from 10.25% in 2023 to 13.34% in 2024, driven by new customer acquisitions [16][24]. TCO Glass Production - The TCO glass segment is approaching a production ramp-up phase, with significant demand expected from downstream customers planning large-scale production between 2025 and 2027 [17][18]. - The company has enhanced its online coating utilization rates post-acquisition, allowing for flexible production capabilities across various glass types [17][18]. - The profitability from TCO glass is expected to contribute significantly to the company's overall net profit in the coming years [17][18].

Investment Rating - The report maintains a "Buy" rating for the company [6][8]. Core Insights - The company is a leading player in the orthopedic surgical robot industry in China, focusing on reshaping surgical processes through intelligent technology and integrating upstream and downstream resources [3][16]. - The company has launched multiple generations of orthopedic surgical robots, with significant advancements in product capabilities and regulatory approvals, including the first all-in-one orthopedic surgical robot [3][5]. - Recent policy changes from the National Medical Insurance Administration are expected to enhance the commercial viability of robotic surgeries, potentially increasing the number of procedures covered by insurance [4][48]. - The company’s revenue from consumables and services is projected to become a major growth driver, supported by an increasing number of surgeries and a growing aging population [5][28]. - Financial forecasts indicate strong revenue growth, with expected revenues of 275 million, 396 million, and 567 million yuan for 2025, 2026, and 2027 respectively, alongside a path to profitability by 2027 [6][9]. Company Overview - The latest closing price of the company's stock is 22.79 yuan, with a total market capitalization of 10.4 billion yuan [2]. - The company has a total share capital of 456 million shares, with a debt-to-asset ratio of 24.3% [2]. Business Model and Ecosystem - The company operates on a "device + consumables + services" model, which has led to synergistic growth across its business segments [24]. - The orthopedic surgical robot business is the core revenue source, with a significant number of surgeries performed using its products [25][29]. - The company has established a stable governance structure with a strong technical background among its management team, ensuring effective operational oversight [19][20]. Market Potential - The global orthopedic surgical robot market is projected to grow significantly, driven by an aging population and the increasing demand for precise surgical interventions [31][36]. - The domestic market for orthopedic surgical robots is expected to maintain high growth rates, with the company positioned as a market leader [41][42]. Financial Performance - The company has maintained a high gross margin, with a sales gross margin of 70.2% in 2024, which is expected to improve further [30]. - Revenue for the first three quarters of 2025 reached 1.87 billion yuan, reflecting a year-on-year growth of 103.5% [29][32].

证券研究报告·北交所公司深度报告·化学制品 锦华新材（920015） 精细化工基石稳固，电子化学品崭露头角 2026 年 02 月 03 日 买入（首次） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 1,115 | 1,239 | 1,064 | 1,209 | 1,507 | | 同比（%） | 12.13 | 11.21 | (14.18) | 13.67 | 24.63 | | 归母净利润（百万元） | 172.51 | 210.94 | 198.77 | 257.08 | 344.23 | | 同比（%） | 116.74 | 22.28 | (5.77) | 29.33 | 33.90 | | EPS-最新摊薄（元/股） | 1.27 | 1.56 | 1.47 | 1.90 | 2.54 | | P/E（现价&最新摊薄） | 39.17 | 32.04 | 34.00 | 26.29 | 19.63 | [Ta ...

[Table_Tag] [Table_Summary] 投资要点 证券研究报告·北交所公司深度报告·化学制品 锦华新材（920015） 精细化工基石稳固，电子化学品崭露头角 2026 年 02 月 03 日 买入（首次） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 1,115 | 1,239 | 1,064 | 1,209 | 1,507 | | 同比（%） | 12.13 | 11.21 | (14.18) | 13.67 | 24.63 | | 归母净利润（百万元） | 172.51 | 210.94 | 198.77 | 257.08 | 344.23 | | 同比（%） | 116.74 | 22.28 | (5.77) | 29.33 | 33.90 | | EPS-最新摊薄（元/股） | 1.27 | 1.56 | 1.47 | 1.90 | 2.54 | | P/E（现价&最新摊薄） | 39.17 | 32 ...